AnaptysBio Q3 net loss $1.14/shr; cash $458M; Phase 2b data catalysts ahead

ANAPTYSBIO, INC

2024-Q3 EPS reported -$4.46 revenue$48,167,000

Net loss $32.9M ($1.14/shr) vs $37.3M ($1.41/shr) year-ago; nine-month loss $4.46/shr.
Collaboration revenue $30M in Q3 vs $3.3M year-ago due to Jemperli milestone and royalties.
Cash and investments $458M; reaffirms cash runway through year-end 2026.
Top-line Phase 2b data for ANB032 in atopic dermatitis expected December 2024.
Top-line Phase 2b data for rosnilimab in RA expected February 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.